Ritual Publishes Prenatal Trial Showing 5-MTHF Can Replace Folic Acid While Cutting UMFA Levels

New updates have been reported about Ritual.

Ritual has released new clinical data on its Essential Prenatal multivitamin, positioning the company more squarely in evidence-based maternal health. In a 24-week randomized, double-blind, controlled trial conducted with Brooklyn College (CUNY) and published in Frontiers in Nutrition, prenatal products using 5-methyltetrahydrofolate (5-MTHF) instead of folic acid maintained maternal and fetal folate status while markedly reducing unmetabolized folic acid (UMFA) in blood and placental tissue.

The study followed 62 women in their second and third trimesters, randomly assigned to multivitamins containing either 5-MTHF or synthetic folic acid through delivery. Outcomes showed no difference in total folate levels between groups, but only 7% of women on 5-MTHF had detectable UMFA versus 31% on folic acid, and UMFA concentrations were lower in both maternal blood and placenta in the 5-MTHF arm, supporting Ritual’s formulation strategy and potential product differentiation.

Folate is critical for DNA synthesis and fetal development, and the data directly address growing concerns about high folic acid intakes and UMFA accumulation among heavy supplement users. By funding and co-designing the trial while relying on an independent academic research team, Ritual is signaling a strategic emphasis on rigorous, peer-reviewed validation of its formulations, which may strengthen credibility with clinicians, regulators, and increasingly science-focused consumers.

Ritual’s Senior Vice President of Science & Innovation framed the work as part of a broader effort to close evidence gaps in prenatal nutrition, particularly in diverse populations; the cohort included a mix of racial and ethnic backgrounds and varied socioeconomic profiles, which may enhance generalizability and support future positioning to health systems and payers. Founder and CEO Katerina Schneider characterized the investment as both a commercial and category-level move to raise research standards in women’s health, an area historically underrepresented in clinical trials.

The company has committed $5 million to complete clinical trials across its full portfolio by 2030, with five studies finished to date and three already published in peer-reviewed journals, indicating a multi-year pipeline of potential data-driven claims. For executives evaluating Ritual, these results strengthen the company’s value proposition as a science-led, privately held women’s health platform and may support premium pricing, healthcare partnerships, and potential exit or capital-raising narratives centered on clinical differentiation rather than purely brand-led growth.